Literature DB >> 16231285

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

Amanda L Cox1, Sara A J Thompson, Joanne L Jones, Vicki H Robertson, Geoff Hale, Herman Waldmann, D Alastair S Compston, Alasdair J Coles.   

Abstract

Following lymphocyte depletion, homeostatic mechanisms drive the reconstitution of lymphocytes. We prospectively studied this process in 16 patients for 1 year after a single pulse of treatment with Campath-1H, a humanised anti-CD52 monoclonal antibody. We observed two phases of lymphocyte reconstitution. In the first 6 months after treatment the precursor frequency and proliferation index of the patients' autologous mixed lymphocyte reaction increased; the depleted T cell pool was dominated by memory T cells, especially (CD4+)CD25high T cells, a putative regulatory phenotype; and there was a non-significant rise in peripheral mononuclear cell FoxP3 mRNA expression and fall in constitutive cytokine mRNA expression. In the later phase, from 6-to-12 months after Campath-1H, these changes reversed and there was a rise in ROG mRNA expression. However, total CD4+ numbers remained below 50% of pre-treatment levels at 12 months, perhaps reflecting a failure in homeostasis. This was not due to an impaired IL-7 response, as in rheumatoid arthritis, nor to a lack of IL-7 receptors, which are found on fewer human (CD4+)CD25high than naive cells. We speculate that CCL21 and IL-15 responses to lymphopaenia may be suboptimal in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16231285     DOI: 10.1002/eji.200535075

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  103 in total

Review 1.  T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Kate O'Brien; Bruno Gran; Abdolmohamad Rostami
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

Review 2.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

Review 3.  Monoclonal antibodies as disease modifying therapy in multiple sclerosis.

Authors:  Erin E Longbrake; Becky J Parks; Anne H Cross
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

4.  Low-intensity transplant regimens facilitate recruitment of donor-specific regulatory T cells that promote hematopoietic engraftment.

Authors:  Ling Weng; Julian Dyson; Francesco Dazzi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-09       Impact factor: 11.205

5.  Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT.

Authors:  Allison L Bayer; Monica Jones; Jackeline Chirinos; Lesley de Armas; Taylor H Schreiber; Thomas R Malek; Robert B Levy
Journal:  Blood       Date:  2008-10-02       Impact factor: 22.113

6.  Efficacy and safety of alemtuzumab in multiple sclerosis and impact on nursing role.

Authors:  Christina Caon; Cathy Meyer; Lori Mayer; M Shelton Smith
Journal:  Int J MS Care       Date:  2013

7.  Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis.

Authors:  Andreas Reiff; Bracha Shaham; Kenneth I Weinberg; Gay M Crooks; Robertson Parkman
Journal:  J Clin Immunol       Date:  2011-05-04       Impact factor: 8.317

Review 8.  Managing Risks with Immune Therapies in Multiple Sclerosis.

Authors:  Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

Review 9.  T Follicular Regulatory Cells and Antibody Responses in Transplantation.

Authors:  Elizabeth F Wallin
Journal:  Transplantation       Date:  2018-10       Impact factor: 4.939

Review 10.  [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].

Authors:  C Warnke; B C Kieseier; U Zettl; H-P Hartung
Journal:  Nervenarzt       Date:  2009-04       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.